Thank you, Rich. We continue to focus on expanding both our asset base and cash flow lending businesses. The combination of these strategies enables SUNS to act as a solutions provider to middle market companies and offers us multiple avenues for portfolio growth. SUNS' comprehensive portfolio totaled $625 million at year-end. It was highly diversified, encompassing 210 borrowers across 100 industries. Approximately 60% of the portfolio was invested in asset based and life science lending strategies, and the remaining 40% was invested in first lien cash flow loans. Across SUNS' portfolio, our largest industry exposures continue to be diversified financial services, healthcare providers and insurance. The average investment per issuer was $3 million or less than 0.5% of the portfolio. At year-end, approximately 100% of the portfolio consisted of first lien loans with no second lien loan exposure and de minimis amount of equity. At year-end, the weighted average asset level yield was 9.7%. By having 60% of the portfolio allocated to our commercial finance verticals, we've been able to maintain attractive asset level yields close to 10% of the portfolio. At year-end, the weighted average investment risk rating remained at 1.8 based on our one to four risk rating scale, with one representing the least amount of risk. Including activity across our four business lines, originations totaled $82 million in the fourth quarter and repayments were $64 million. Originations for the full year 2021 were $357 million. Additionally, SUNS has $43 million of unfunded delayed draw commitments at year-end, which should support further growth into 2022. We believe that these delayed draw term loan transactions offer prudent opportunity for SUNS to continue to grow its investment and establish credits with existing financial covenants. Now, let me provide an update on each of our investment verticals. I'll start with cash flow. Our portfolio in cash flow segment was just over $250 million or approximately 40% of the comprehensive portfolio. We have invested across 35 borrowers, with an average investment of just over $7 million. As I mentioned, a 100% of this portfolio is first lien cash flow investments. Average EBITDA for our borrowers was over $100 million, reflecting our strong preference to finance larger companies in the upper mid-market. The weighted average yield for this portfolio was just over 6.5%. During the fourth quarter, we originated just over $38 million of cash flow loans and had repayments of just over $30 million. For the full year, we originated $153 million of cash flow investments. We're encouraged that sponsor activity picked up in 2021, with significantly higher volumes of M&A. We expect that momentum to continue this year, which we believe will provide additional opportunities to invest in attractive, resilient upper mid-market cash flow companies. Now, let me turn to our asset based lending businesses. As a reminder, SUNS owns two commercial finance companies that specialize in making first lien, asset-backed loans collateralized by accounts receivable. These portfolio companies lend to small and mid-sized U.S. companies, who typically have limited access to more traditional bank financing. The first of these is Business Credit. Business Credit's portfolio was just over $250 million or 40% of our comprehensive portfolio at year-end, consisted of over 125 borrowers with an average investment of $2 million. Utilization rates on Business Credit's working capital facilities have continued to increase back towards pre-COVID levels. Last summer, Business Credit acquired FastPay, a digital media factoring platform. The integration has gone extremely well, with FastPay proving to have strengthened Business Credit's origination capabilities. The pipeline remains strong driven both by improved utilization rates of existing facilities, as well as new investment opportunities. The weighted average asset yield on Business Credit's portfolio was just over 12% for the fourth quarter. For the fourth quarter, Business Credit paid a cash dividend up to SUNS of $1.65 million, which represented a 10% increase from the third quarter. Now let me touch on Healthcare ABL. Portfolio was just under $90 million at year-end, representing 14% of our total portfolio at SUNS. It was comprised of loans to 36 borrowers with an average funded investment of $2.5 million. The portfolio remains 100% performing and has had no payment defaults since the commencement of COVID. The weighted average asset level yield was approximately 11% during the fourth quarter. During this fourth quarter, they funded just over $12 million of new loans, and for the year funded just under $50 million of investments. Similar to Business Credit, Healthcare ABL was impacted by the stimulus programs, which enable borrowers to significantly reduce their funded balances on our facilities. As these programs have tapered off, borrowers have begun to draw down under our facilities at Healthcare ABL and has increased our outstandings to pre-COVID levels. For the fourth quarter, the company paid a cash dividend of $900,000, consistent with the prior quarter. Finally, let me provide an update on our life science vertical. At year-end, the portfolio totaled $33 million across nine different borrowers. The weighted average yield on this portfolio was approximately 10% at cost, which excludes success fees and warrants. While life science loans represent 5% of SUNS portfolio, they generated 11% of our gross investment income for the year. The opportunity set to invest in larger, more established life science businesses continues to increase, which we expect will benefit SUNS through additional origination activity this year. Overall, we believe that SUNS is well-positioned to take advantage of an improving economy and a more robust opportunity set across each of our verticals. SLR Capital Partners' diversified commercial finance platform and significant dry powder enables SUNS to provide structured solutions, both cash flow and asset based loans. Given our current pipeline, we expect SUNS to continue to grow this portfolio in 2022. Now, let me turn the call back to Michael.